ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $88,180,890 | -20.9% | 4,395,857 | +11.3% | 0.00% | 0.0% |
| Q2 2023 | $111,452,179 | +89.6% | 3,950,804 | +15.6% | 0.00% | +50.0% |
| Q1 2023 | $58,780,432 | -15.9% | 3,417,467 | -1.6% | 0.00% | 0.0% |
| Q4 2022 | $69,929,685 | -3.2% | 3,472,179 | +4.1% | 0.00% | 0.0% |
| Q3 2022 | $72,258,000 | -20.7% | 3,336,066 | +2.9% | 0.00% | -33.3% |
| Q2 2022 | $91,074,000 | -30.6% | 3,241,058 | +14.0% | 0.00% | -25.0% |
| Q1 2022 | $131,158,000 | -45.1% | 2,842,580 | -0.0% | 0.00% | -33.3% |
| Q4 2021 | $238,978,000 | +30.1% | 2,842,945 | +3.2% | 0.01% | +20.0% |
| Q3 2021 | $183,645,000 | +48.8% | 2,755,788 | +18.8% | 0.01% | +66.7% |
| Q2 2021 | $123,429,000 | +24.9% | 2,320,116 | +1.9% | 0.00% | 0.0% |
| Q1 2021 | $98,789,000 | -16.4% | 2,276,773 | +0.1% | 0.00% | -25.0% |
| Q4 2020 | $118,172,000 | +276.6% | 2,275,149 | +137.0% | 0.00% | +300.0% |
| Q3 2020 | $31,382,000 | -28.4% | 960,008 | +5.2% | 0.00% | -50.0% |
| Q2 2020 | $43,821,000 | – | 912,549 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |